| The rational development of CD133-targeting immunotherapies for glioblastoma P Vora, C Venugopal, SK Salim, N Tatari, D Bakhshinyan, M Singh, ... Cell Stem Cell 26 (6), 832-844. e6, 2020 | 154 | 2020 |
| CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment M Seyfrid, WT Maich, MV Shaikh, N Tatari, D Upreti, D Piyasena, ... Journal for immunotherapy of cancer 10 (1), 2022 | 46 | 2022 |
| Chemorepellent semaphorin 3E negatively regulates neutrophil migration in vitro and in vivo H Movassagh, A Saati, S Nandagopal, A Mohammed, N Tatari, L Shan, ... The Journal of Immunology 198 (3), 1023-1033, 2017 | 46 | 2017 |
| Wnt activation as a therapeutic strategy in medulloblastoma B Manoranjan, C Venugopal, D Bakhshinyan, AA Adile, L Richards, ... Nature Communications 11 (1), 4323, 2020 | 44 | 2020 |
| A CD133-AKT-Wnt signaling axis drives glioblastoma brain tumor-initiating cells B Manoranjan, C Chokshi, C Venugopal, M Subapanditha, N Savage, ... Oncogene 39 (7), 1590-1599, 2020 | 44 | 2020 |
| Targeting the Siglec–sialic acid axis promotes antitumor immune responses in preclinical models of glioblastoma P Schmassmann, J Roux, A Buck, N Tatari, S Hogan, J Wang, ... Science translational medicine 15 (705), eadf5302, 2023 | 34 | 2023 |
| CD271+ Cells Are Diagnostic and Prognostic and Exhibit Elevated MAPK Activity in SHH Medulloblastoma L Liang, L Coudière-Morrison, N Tatari, M Stromecki, A Fresnoza, ... Cancer Research 78 (16), 4745-4759, 2018 | 34 | 2018 |
| Human airway smooth muscle cell proliferation from asthmatics is negatively regulated by semaphorin3A H Movassagh, N Tatari, L Shan, L Koussih, D Alsubait, M Khattabi, ... Oncotarget 7 (49), 80238, 2016 | 33 | 2016 |
| Characterization of novel biomarkers in selecting for subtype specific medulloblastoma phenotypes L Liang, C Aiken, R McClelland, LC Morrison, N Tatari, M Remke, ... Oncotarget 6 (36), 38881, 2015 | 29 | 2015 |
| Characterization of a novel OTX 2‐driven stem cell program in Group 3 and Group 4 medulloblastoma M Stromecki, N Tatari, LC Morrison, R Kaur, J Zagozewski, G Palidwor, ... Molecular oncology 12 (4), 495-513, 2018 | 28 | 2018 |
| The proteomic landscape of glioblastoma recurrence reveals novel and targetable immunoregulatory drivers N Tatari, S Khan, J Livingstone, K Zhai, D Mckenna, V Ignatchenko, ... Acta neuropathologica 144 (6), 1127-1142, 2022 | 22 | 2022 |
| Semaphorin 3E Inhibits House Dust Mite–Induced Angiogenesis in a Mouse Model of Allergic Asthma N Tatari, H Movassagh, L Shan, L Koussih, AS Gounni The American journal of pathology 189 (4), 762-772, 2019 | 22 | 2019 |
| Advances in immunotherapy for adult glioblastoma CR Chokshi, BA Brakel, N Tatari, N Savage, SK Salim, C Venugopal, ... Cancers 13 (14), 3400, 2021 | 13 | 2021 |
| Temporal profiling of therapy resistance in human medulloblastoma identifies novel targetable drivers of recurrence D Bakhshinyan, AA Adile, J Liu, WD Gwynne, Y Suk, S Custers, I Burns, ... Science Advances 7 (50), eabi5568, 2021 | 12 | 2021 |
| In vitro self-renewal assays for brain tumor stem cells M Seyfrid, D Bobrowski, D Bakhshinyan, N Tatari, C Venugopal, SK Singh Brain Tumor Stem Cells: Methods and Protocols, 79-84, 2019 | 9 | 2019 |
| Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastoma MA Qazi, SK Salim, KR Brown, N Mikolajewicz, N Savage, H Han, ... Cell Reports 40 (13), 2022 | 8 | 2022 |
| Dual antigen T cell engagers targeting CA9 as an effective immunotherapeutic modality for targeting CA9 in solid tumors N Tatari, X Zhang, SC Chafe, D McKenna, KA Lawson, M Subapanditha, ... Frontiers in Immunology 13, 905768, 2022 | 8 | 2022 |
| Preclinical testing of CAR T cells in a patient-derived xenograft model of glioblastoma N Tatari, WT Maich, SK Salim, D Mckenna, C Venugopal, S Singh STAR protocols 1 (3), 100174, 2020 | 8 | 2020 |
| An HLA-G/SPAG9/STAT3 axis promotes brain metastases BI Bassey-Archibong, C Rajendra Chokshi, N Aghaei, AM Kieliszek, ... Proceedings of the National Academy of Sciences 120 (8), e2205247120, 2023 | 4 | 2023 |
| Real-time evaluation of a hydrogel delivery vehicle for cancer immunotherapeutics within embedded spheroid cultures V Huynh, N Tatari, A Marple, N Savage, D McKenna, C Venugopal, ... Journal of Controlled Release 348, 386-396, 2022 | 4 | 2022 |
